Recommended

AstraZeneca boosts production capacity at Texas facility following $445m investment
ESMO 2025: Keytruda immunotherapy shows promise in skin cancer
AstraZeneca research illustrates potential of autonomous UVC disinfection in pharma cleanrooms
Webinar: Radiopharmaceuticals’ time-to-result challenge
Ipsen €1bn ImCheck Therapeutics acquisition deal
Phase III data for next-gen green inhaler push GSK closer to Net Zero targets
Lilly progresses Incyte’s JAK inhibitor in major study
news

New EVP, Teva Global Operations appointed

0
SHARES

The new Executive Vice President of Teva Global Operations will bring “significant experience at every stage of the manufacturing and supply process” to his new role, the company asserted.

Teva manufacturing

[Credit: JHVEPhoto/Shutterstock.com].

Matthew Shields has been appointed as Executive Vice President of Teva Pharmaceutical Industries Ltd.’s manufacturing and supply division.

 

ACCESS your FREE COPY

 


This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.

Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.

What you’ll discover:

  • Key trends shaping the pharmaceutical formulation sector
  • Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
  • Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
  • And more!

Don’t miss your chance to access this exclusive report ! Access now – it’s free

His position within Teva Global Operations will commence on 3 June 2024. He will be part of the company’s Executive Leadership Team and be based at Teva’s US headquarters. Mr Shields stated that he is “honoured” to take on his new role.

Teva’s new appointment

Teva explained that with over 25 years of experience in the global biopharmaceutical and animal health industries, Mr Shields brings “significant experience at every stage of the manufacturing and supply process”.

Richard Francis, Teva’s President and CEO commented that he is “thrilled” with the new appointment, citing that Mr Shields will help the company to deliver its support to patients and healthcare systems globally.

Mr Shields will take over from Eric Drapé, who has been with the company for 11 years. This includes over four years as Executive Vice President, Global Operations, according to the pharmaceutical organisation.

Previous roles

MATTHEW SHIELDS EXECUTIVE VICE PRESIDENT, TEVA GLOBAL OPERATIONS

Matthew Shields appointed to Executive Vice President, Teva Global Operations (Photo: Business Wire)

In his most recent role, Mr Shields served as Senior Vice President for Animal Health Manufacturing for Merck, known as MSD Animal Health outside of the United States and Canada. This position involved overseeing end-to-end manufacturing, supply chain, procurement, and process development. He also led Specialty Care Manufacturing, Engineering, and Operational Excellence for Sanofi, Teva noted.

In his role as Global Head of Sanofi’s Specialty Care Manufacturing organisation, Mr Shields worked to facilitate successful launches of Dupixent® and Praluent®, Teva stated. He also oversaw the commissioning and startup of Sanofi’s first digitally enabled continuous manufacturing facility.

Early in his career, Mr Shields worked in various leadership roles in Operations at Amgen, Teva stated.

Mr Shields has an undergraduate degree in Chemical Engineering & Materials Science Engineering from the University of Connecticut. Teva added that he also holds an MBA from Bryant University in Rhode Island. At present, Mr Shields is a member of the board of the National Association of Manufacturers.

Share via
Share via